György Losonczy

Researcher Next ID · RN-014007

Researcher · Medicine

, Hungary

Not currently recruitingFunding unknown

Research interests

Medicine

Lung Cancer Research Studies

Neuroendocrine Tumor Research Advances

Peptidase Inhibition and Analysis

Asthma and respiratory diseases

Lung Cancer Treatments and Mutations

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30539-8
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30539-8
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
The Lancet · 2019 · 10.1016/s0140-6736(19)32222-6
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 10.1056/nejmoa1809064

No projects listed.